{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    19,
    20,
    21,
    22,
    23,
    24
  ],
  "modelUsed": "gemini-2.5-pro",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To demonstrate the superiority of palbociclib in combination with fulvestrant (with or without goserelin) over fulvestrant alone (with or without goserelin) in prolonging investigator-assessed PFS in women with HR+/HER2-negative metastatic breast cancer whose disease has progressed on prior endocrine therapy.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Tumor Control Objective",
        "text": "To compare measures of tumor control between the treatment arms.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2",
          "ep_3",
          "ep_4",
          "ep_5",
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Safety and Tolerability Objective",
        "text": "To compare safety and tolerability between the treatment arms.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Palbociclib Pharmacokinetic Objective",
        "text": "To evaluate trough concentrations of palbociclib when given in combination with fulvestrant or fulvestrant plus goserelin, compared to historical palbociclib data.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Fulvestrant and Goserelin Pharmacokinetic Objective",
        "text": "To compare fulvestrant and goserelin trough concentrations when given in combination with palbociclib to those when given without palbociclib.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Exposure-Response Objective",
        "text": "To explore correlations between palbociclib exposures and efficacy/safety findings in this patient population.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Patient Reported Outcomes Objective",
        "text": "To compare Patient Reported Outcomes measures between treatment arms.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Biomarker Objective",
        "text": "To characterize alterations in genes, proteins, and ribonucleic acids (RNAs) relevant to the cell cycle, drug targets, tumor sensitivity and/or resistance.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Subgroup Analysis Objective",
        "text": "To conduct subgroup analysis for primary and secondary endpoints in stratified groups.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Progression-Free Survival (PFS)",
        "text": "Progression-Free Survival (PFS) as assessed by the Investigator.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Overall Survival (OS)",
        "text": "Overall Survival (OS).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Survival Probabilities",
        "text": "1-year, 2-year, and 3-year survival probabilities.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Objective Response (OR)",
        "text": "Objective Response (OR): Complete Response (CR) or Partial Response (PR).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Duration of Response (DR)",
        "text": "Duration of Response (DR).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Clinical Benefit Response (CBR)",
        "text": "Clinical Benefit Response (CBR): CR or PR or Stable Disease (SD) ≥24 weeks.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Adverse Events and Laboratory Abnormalities",
        "text": "Type, incidence, severity (as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.0), seriousness and relationship to study medications of Adverse Events (AEs) and any laboratory abnormalities.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_8",
        "name": "Trough Plasma Concentrations",
        "text": "Trough plasma concentration of palbociclib, fulvestrant and goserelin (if applicable) in the subgroup of approximately 40 patients included in the initial safety review.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_9",
        "name": "Patient Reported Outcomes (PRO)",
        "text": "PRO endpoints such as global quality of life symptoms and functioning assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Instrument (EORTC QLQ-C30) and European Organisation for Research and Treatment of Cancer Breast Cancer Module (EORTC QLQ-BR23) and Dimension Health State EuroQoL Score (EQ-5D)and time to deterioration (TTD) in pain endpoint.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_10",
        "name": "Tumor Tissue Biomarkers",
        "text": "Tumor tissue biomarkers, including genes (eg, copy numbers of CCND1 and CDKN2A, PIK3CA mutations), proteins (eg, Ki67, pRb, CCNE1), and RNA expression (eg, cdk4, cdk6).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      }
    ],
    "estimands": [],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 8,
      "exploratoryObjectives": 0,
      "totalEndpoints": 10,
      "totalEstimands": 0
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To demonstrate the superiority of palbociclib in combination with fulvestrant (with or without goserelin) over fulvestrant alone (with or without goserelin) in prolonging investigator-assessed PFS in women with HR+/HER2-negative metastatic breast cancer whose disease has progressed on prior endocrine therapy.",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Primary Objective"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Tumor Control Objective",
        "text": "To compare measures of tumor control between the treatment arms.",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_2",
          "ep_3",
          "ep_4",
          "ep_5",
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Safety and Tolerability Objective",
        "text": "To compare safety and tolerability between the treatment arms.",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Palbociclib Pharmacokinetic Objective",
        "text": "To evaluate trough concentrations of palbociclib when given in combination with fulvestrant or fulvestrant plus goserelin, compared to historical palbociclib data.",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Fulvestrant and Goserelin Pharmacokinetic Objective",
        "text": "To compare fulvestrant and goserelin trough concentrations when given in combination with palbociclib to those when given without palbociclib.",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Exposure-Response Objective",
        "text": "To explore correlations between palbociclib exposures and efficacy/safety findings in this patient population.",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Patient Reported Outcomes Objective",
        "text": "To compare Patient Reported Outcomes measures between treatment arms.",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Biomarker Objective",
        "text": "To characterize alterations in genes, proteins, and ribonucleic acids (RNAs) relevant to the cell cycle, drug targets, tumor sensitivity and/or resistance.",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Subgroup Analysis Objective",
        "text": "To conduct subgroup analysis for primary and secondary endpoints in stratified groups.",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Progression-Free Survival (PFS)",
        "text": "Progression-Free Survival (PFS) as assessed by the Investigator.",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_2",
        "name": "Overall Survival (OS)",
        "text": "Overall Survival (OS).",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_3",
        "name": "Survival Probabilities",
        "text": "1-year, 2-year, and 3-year survival probabilities.",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_4",
        "name": "Objective Response (OR)",
        "text": "Objective Response (OR): Complete Response (CR) or Partial Response (PR).",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_5",
        "name": "Duration of Response (DR)",
        "text": "Duration of Response (DR).",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_6",
        "name": "Clinical Benefit Response (CBR)",
        "text": "Clinical Benefit Response (CBR): CR or PR or Stable Disease (SD) ≥24 weeks.",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_7",
        "name": "Adverse Events and Laboratory Abnormalities",
        "text": "Type, incidence, severity (as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.0), seriousness and relationship to study medications of Adverse Events (AEs) and any laboratory abnormalities.",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_8",
        "name": "Trough Plasma Concentrations",
        "text": "Trough plasma concentration of palbociclib, fulvestrant and goserelin (if applicable) in the subgroup of approximately 40 patients included in the initial safety review.",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Pharmacokinetic",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_9",
        "name": "Patient Reported Outcomes (PRO)",
        "text": "PRO endpoints such as global quality of life symptoms and functioning assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Instrument (EORTC QLQ-C30) and European Organisation for Research and Treatment of Cancer Breast Cancer Module (EORTC QLQ-BR23) and Dimension Health State EuroQoL Score (EQ-5D)and time to deterioration (TTD) in pain endpoint.",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "QualityOfLife",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_10",
        "name": "Tumor Tissue Biomarkers",
        "text": "Tumor tissue biomarkers, including genes (eg, copy numbers of CCND1 and CDKN2A, PIK3CA mutations), proteins (eg, Ki67, pRb, CCNE1), and RNA expression (eg, cdk4, cdk6).",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Biomarker",
        "instanceType": "Endpoint"
      }
    ],
    "estimands": []
  }
}